<img height="1" width="1" src="https://www.facebook.com/tr?id=1582471781774081&amp;ev=PageView%20%20&amp;noscript=1">



Fusion Models

Fusion oncogenic events are important targets for oncology research, potentially providing ‘druggable’ targets for subsets of cancer patients. We currently provide FactSheets on:

  • RET fusion in CRC PDX models, including model response to RET inhibitor treatment, and the development of acquired resistance models
  • FGFR3-TACC3 fusion in NSCLC and brain tumor PDX models, as well as bladder cancer Cell Line Derived Xenograft models. The FactSheet includes a wide range of treatment data and development of in vivo and in vitro resistance models